HALO
$65.13
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...
Recent News
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness
Halozyme Therapeutics (NasdaqGS:HALO) has appointed David Ramsay as Interim Chief Financial Officer. Ramsay, a former finance leader at the company with extensive biotechnology experience, will oversee financial operations during the search for a permanent CFO. The leadership change comes at a time when the company continues to manage growth initiatives and capital allocation priorities. For investors watching Halozyme Therapeutics, the CFO transition lands against a mixed share price...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback
If you are wondering whether Halozyme Therapeutics at around US$69.40 is still attractively priced or starting to look expensive, you are in the right place. The share price closed at US$69.40, with returns of a 1.4% decline over 7 days, a 3.2% decline over 30 days, a 1.3% decline year to date, but 19.4% over 1 year, 59.9% over 3 years and 65.8% over 5 years, which can shape how the market is currently weighing its risks and opportunities. Recent attention on Halozyme has been influenced by...
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns
Halozyme Therapeutics overview after recent share performance Halozyme Therapeutics (HALO) has drawn attention after recent share moves, with the stock showing a small 1 day decline and a modest 7 day and month pullback, while the past 3 months remain positive. See our latest analysis for Halozyme Therapeutics. At a share price of $69.40, Halozyme Therapeutics is giving back some recent gains, with short term share price returns softening. However, longer term total shareholder returns over...
Is Halozyme Therapeutics (HALO) a Buy Post Earnings?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received several bullish rating updates from analysts following its earnings release. Morgan Stanley lifted the price target on the stock to $94 from $78 on February 19, maintaining an Overweight rating on the shares after […]